Two Hot Stocks for Tuesday
Investors have two technology companies that will open higher this morning.Palantir (PLTR) may open at around 15% after the company posted fourth-quarter results late Monday. The software AI supplier reported a 36% jump Y/Y in revenue, to $827.52 million. It closed an impressive 129 deals worth at least $1 million in the quarter. In Q1, the company expects revenue of between $858 million and $862 million. This is above the $800 million consensus estimate.Palantir staff who were rewarded market-vesting stock appreciation rights will enjoy substantial gains. PLTR stock gained 421.54% in the last year, excluding this morning’s rise.China’s Kingsoft Cloud (KC) gained nearly 28% in the last five days on no news. Speculators bet on unsubstantiated claims that Xiaomi (XIACF) poached DeepSeek’s Lei Jun. Traders should take advantage of KC stock’s rally by booking profits.Among the stocks facing selling pressure, watch out for FedEx (FDX). The package delivery supplier fell in sympathy with UPS (UPS). Last week, UPS said it expected profit margins and earnings to increase in 2025. However, UPS will struggle to offset client business losses. It lost around half of its Amazon (AMZN) business.Continue to avoid Moderna (MRNA). Covid vaccine sales will weaken as the flu season winds down. In addition, Moderna does not have a robust pipeline to offset weaker vaccine demand.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


